Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="1" name="CC Event Nav"]

Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Sustained Overall Survival in Patients with Smoldering Myeloma Receiving Lenalidomide-Based Therapy

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry

Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma

Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen

PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy

Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma

A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse

Page 18 of 25
Results 171 - 180 of 242